BR112022002309A2 - Conjugado e usos do mesmo - Google Patents

Conjugado e usos do mesmo

Info

Publication number
BR112022002309A2
BR112022002309A2 BR112022002309A BR112022002309A BR112022002309A2 BR 112022002309 A2 BR112022002309 A2 BR 112022002309A2 BR 112022002309 A BR112022002309 A BR 112022002309A BR 112022002309 A BR112022002309 A BR 112022002309A BR 112022002309 A2 BR112022002309 A2 BR 112022002309A2
Authority
BR
Brazil
Prior art keywords
conjugate
treatment
present
therapeutic molecule
peptide carrier
Prior art date
Application number
BR112022002309A
Other languages
English (en)
Inventor
Arnaud Klein
Ashling Holland
Denis Furling
Matthew Wood
Michael Gait
Miguel Varela
Richard Raz
Original Assignee
Association Inst De Myologie
Inst Nat Sante Rech Med
Univ Oxford Innovation Ltd
Univ Sorbonne
Res & Innovation Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association Inst De Myologie, Inst Nat Sante Rech Med, Univ Oxford Innovation Ltd, Univ Sorbonne, Res & Innovation Uk filed Critical Association Inst De Myologie
Publication of BR112022002309A2 publication Critical patent/BR112022002309A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

conjugado e usos do mesmo a presente invenção se refere a conjugados formados a partir de um carreador peptídico de penetração celular ligado a uma molécula terapêutica, em que o carreador peptídico é definido por domínios específicos e a molécula terapêutica é um ácido nucleico formado de repetições de trinucleotídeos. a presente invenção se refere ainda ao uso de um tal conjugado em métodos de tratamento ou como um medicamento, especialmente no tratamento de distúrbios de repetição de trinucleotídeos tal como distrofia miotônica (dm1).
BR112022002309A 2019-08-09 2020-08-07 Conjugado e usos do mesmo BR112022002309A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1911403.2A GB201911403D0 (en) 2019-08-09 2019-08-09 Conjugate and uses thereof
PCT/GB2020/051891 WO2021028666A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof

Publications (1)

Publication Number Publication Date
BR112022002309A2 true BR112022002309A2 (pt) 2022-04-26

Family

ID=67990936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002309A BR112022002309A2 (pt) 2019-08-09 2020-08-07 Conjugado e usos do mesmo

Country Status (12)

Country Link
US (1) US20220275372A1 (pt)
EP (1) EP4010030A1 (pt)
JP (1) JP2022543320A (pt)
KR (1) KR20220079524A (pt)
CN (1) CN114615998A (pt)
AU (1) AU2020327659A1 (pt)
BR (1) BR112022002309A2 (pt)
CA (1) CA3149700A1 (pt)
GB (1) GB201911403D0 (pt)
IL (1) IL290424A (pt)
MX (1) MX2022001712A (pt)
WO (1) WO2021028666A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511954A (ja) * 2021-03-12 2024-03-18 ペプゲン インコーポレイテッド． ペプチド－オリゴヌクレオチド複合体を用いる筋強直性ジストロフィー１型の治療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP2011523557A (ja) * 2008-06-04 2011-08-18 メディカル リサーチ カウンシル ペプチド
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP6077543B2 (ja) * 2011-08-30 2017-02-08 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ ペプチド
RU2018123569A (ru) * 2012-09-25 2019-03-07 Джензим Корпорейшн Связанные с пептидом морфолиновые антисмысловые олигонуклеотиды для лечения миотонической дистрофии
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения

Also Published As

Publication number Publication date
CA3149700A1 (en) 2021-02-18
AU2020327659A1 (en) 2022-02-24
MX2022001712A (es) 2022-05-13
EP4010030A1 (en) 2022-06-15
KR20220079524A (ko) 2022-06-13
GB201911403D0 (en) 2019-09-25
IL290424A (en) 2022-04-01
WO2021028666A1 (en) 2021-02-18
JP2022543320A (ja) 2022-10-11
US20220275372A1 (en) 2022-09-01
CN114615998A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
BRPI0622298A8 (pt) Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
BR112014026703A2 (pt) inibidores de dna-pk
BR112015014333A2 (pt) compostos antivirais
NZ543467A (en) The severe acute respiratory syndrome coronavirus
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
BRPI1012749A8 (pt) molécula de ligação, variante funcional da molécula de ligação, imunoconjugado, composição farmacêutica, uso da molécula de ligação, molécula de ácido nucléico. vetor, hospedeiro, e , método para produzir uma molécula de ligação.
ATE485304T1 (de) Muteine von tearlipocalin und verfahren zu deren gewinnung
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
BRPI0519593A2 (pt) composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
CU20080028A6 (es) Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BRPI0507236A (pt) método para o tratamento ou profilaxia de uma condição, e, composto
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112015018491A2 (pt) triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
WO2017180789A8 (en) Methods of treatment using chlorotoxin conjugates
BR112015012051A2 (pt) composições e métodos para modulação de expressão de fgfr3
BR112015011896A2 (pt) derivado fotorreativo de ácido hialurônico, método de preparação do derivado fotorreativo, método de preparação de derivados 3d reticulados de ácido hialurônico, derivado 3d reticulado de ácido hialurônico e uso do derivado 3d reticulado